Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study

Documenti analoghi

• Use of Hospital‐at‐Home Services for Injectable Chemotherapy for Patients With Multiple Myeloma in France in 2019 and 2020: A Real‐World Nationwide Study Based on the French Hospital Discharge Database
  di: Laure Vincent, et al.
  Pubblicazione: (2025)
• Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
  di: Syed Naqvi, et al.
  Pubblicazione: (2024)
• The evolving treatment landscape of multiple myeloma in Portugal: A nation‐wide retrospective cohort study of real‐world clinical practice
  di: Rui Bergantim, et al.
  Pubblicazione: (2024)
• “Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma
  di: Kevin C. Graf, et al.
  Pubblicazione: (2024)
• Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy
  di: Francesca Fazio, et al.
  Pubblicazione: (2024)